The systemic administration of nanoparticles activates an inflammatory response because of the accumulation of blood components on their surface. This was demonstrated by a Houston Methodist-led research team, and this finding could help researchers to develop more efficient ways that will help prevent the activation of the immune system and direct therapies in patients in a more precise manner.

The team recently explained how specially-engineered nanoparticles (leukosomes) injected into mice can help prevent the development of a layer of biomolecules (protein corona) surrounding their surface. This explanation was presented by the team in the journal ACS Nano.